173 related articles for article (PubMed ID: 36323540)
1. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].
Duan ZJ; Feng J; Yao K; Hu ZJ; Ma Z; Xiang L; Zhang XF; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1115-1122. PubMed ID: 36323540
[No Abstract] [Full Text] [Related]
2. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
3. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
[TBL] [Abstract][Full Text] [Related]
4. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
[No Abstract] [Full Text] [Related]
5. NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.
Dahl NA; Donson AM; Sanford B; Wang D; Walker FM; Gilani A; Foreman NK; Tinkle CL; Baker SJ; Hoffman LM; Venkataraman S; Vibhakar R
J Neuropathol Exp Neurol; 2021 Mar; 80(4):345-353. PubMed ID: 33749791
[TBL] [Abstract][Full Text] [Related]
6. [Diffuse midline gliomas with H3K27 alteration in children: a clinicopathological analysis of forty-one cases].
Li J; Ma YY; Feng J; Zhao D; Ding F; Tian L; Chen R; Zhao R
Zhonghua Bing Li Xue Za Zhi; 2022 Apr; 51(4):319-325. PubMed ID: 35359043
[No Abstract] [Full Text] [Related]
7. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
[TBL] [Abstract][Full Text] [Related]
8. H3K27M Mutation Doesn't Mean Worse Prognosis in Old Patients.
Hu XM; Nie XY; Xu KL; Wang Y; Tang F; Du ZG; Xiong J
Front Oncol; 2022; 12():912166. PubMed ID: 35756637
[TBL] [Abstract][Full Text] [Related]
9. Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review.
Watanabe G; Wong JM; Estes B; Khan MF; Ogasawara C; Umana GE; Martin AR; Bloch O; Palmisciano P
J Neurooncol; 2024 Feb; 166(3):379-394. PubMed ID: 38342826
[TBL] [Abstract][Full Text] [Related]
10. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
11. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.
Enomoto T; Aoki M; Hamasaki M; Abe H; Nonaka M; Inoue T; Nabeshima K
Neurol Med Chir (Tokyo); 2020 Mar; 60(3):136-146. PubMed ID: 31902873
[TBL] [Abstract][Full Text] [Related]
12. Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis.
Wang YZ; Zhang YW; Liu WH; Chai RC; Cao R; Wang B; An SY; Jiang WJ; Xu YL; Yang J; Jia WQ
Neurosurgery; 2021 Jul; 89(2):300-307. PubMed ID: 34015818
[TBL] [Abstract][Full Text] [Related]
13. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
[TBL] [Abstract][Full Text] [Related]
14. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Five Adult Cases of H3K27-Altered Diffuse Midline Glioma in the Spinal Cord.
Gu Q; Huang Y; Zhang H; Jiang B
Front Oncol; 2021; 11():701113. PubMed ID: 34956856
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract][Full Text] [Related]
17. Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas.
Raab P; Banan R; Akbarian A; Esmaeilzadeh M; Samii M; Samii A; Bertalanffy H; Lehmann U; Krauss JK; Lanfermann H; Hartmann C; Brüning R
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326549
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological and molecular characteristics of NTRK-rearranged spindle cell neoplasms in the gastrointestinal tract].
Jian XY; Gao HQ; Zhao ZH; Wang F; Zhang L; Ma YH
Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):598-604. PubMed ID: 38825906
[No Abstract] [Full Text] [Related]
19. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
20. Prediction of H3K27M mutation status of diffuse midline gliomas using MRI features.
Chauhan RS; Kulanthaivelu K; Kathrani N; Kotwal A; Bhat MD; Saini J; Prasad C; Chakrabarti D; Santosh V; Uppar AM; Srinivas D
J Neuroimaging; 2021 Nov; 31(6):1201-1210. PubMed ID: 34189806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]